- Company
- AstraZeneca takes back local sales from GC and Daewoong
- by Eo, Yun-Ho Nov 21, 2019 11:40pm
- AstraZeneca is taking back some local sales rights from GC Pharma and Daewoong Pharmaceutical. According to pharmaceutical industry source on Nov. 1, AstraZeneca Korea has recently decided to retrieve local sales and distribution rights of a high blood pressure treatment, Atacand (candesartan) from GC Pharma, and of chronic obstructive
- Company
- Oral GLP-1 competitiveness depends on price and convenience
- by Nho, Byung Chul Nov 20, 2019 11:50pm
- Although an oral GLP-1 drug, Rybelsus has attracted heightened attention from its market since its recent approval by the U.S. Food and Drug Administration (FDA), it faces some barriers to overcome like inconvenient high-dose regimen and expensive price. Reportedly, once-daily Rybelsus’ effect of glucose control and weight loss is no
- Company
- JW Pharmaceutical’s R&D generates fruitful return
- by Chon, Seung-Hyun Nov 20, 2019 06:14pm
- For this year’s third quarter, JW Pharmaceutical recognized total 6.6 billion won made from exporting drug candidate technology. The amount includes upfront fees received from technology transfer deal from last year over atopic dermatitis drug candidate, and from technology export deal on anti-gout drug candidate made last September. The indust
- Company
- Boycott against Japan makes no impact on drug sector
- by Kim, Jin-Gu Nov 20, 2019 06:33am
- Although this year’s deficit generated from trade with Japan is expected to hit the lowest point, the pharmaceutical sector has not been affected on a notable level. For last six years, Japanese drug import volume skyrocketed by around 57 percent. The import volume easily overwhelmed the Korean export volume, resulting in inevitable heavy d
- Company
- Korean companies into new drug R&D-specializing subsidiaries
- by Lee, Seok-Jun Nov 20, 2019 06:31am
- Growing number of Korean companies are launching subsidiaries solely dedicated for new drug R&D. The companies are taking a concentration strategy on their drug pipelines. Some say the subsidiaries could be used in the future as strategic options, such as means of fund raising or corporate listing. Crystal establishes M&A-specia
- Company
- Ferinject for bloodless surgery, reimbursement started up
- by Nho, Byung Chul Nov 20, 2019 06:19am
- It is noted whether high dose iron injection, Ferinject may be included as insurance reimbursement for bloodless surgery (Minimal Transfusion). According to the industry, JW Pharmaceutical applied for a non-reimbursement item, Ferinject, to HIRA on the 18th. High-dose iron is effective as a transfusion replacement therapy for surgical
- Company
- Power of Innovative Drugs, Keytruda & Spinraza Shake Market
- by Chon, Seung-Hyun Nov 19, 2019 06:34am
- New products, which are regarded as innovative new drugs in the domestic pharmaceutical market, are shaking the upper hand. Keytruda, an immunocancer drug, spearheaded Lipitor to the chin with a steep rise. Rare disorder treatment “Spinraza” presented a remarkable quarterly sales of &8361;20 billion immediately after applying for health i
- Company
- Kolon Life Science faces 88.5-billion-won damage lawsuits
- by Kim, Jin-Gu Nov 18, 2019 10:21pm
- Kolon Life Science is facing a series of damage lawsuits asking for 88.5 billion won as compensation for the Invossa incident. Kolon Life Science stated in the third quarter report that the company’s properties have been seized by Mitsubishi Tanabe and outstanding contract payment from Mundipharma has been suspended. It is facing number of
- Company
- AI-driven Drug Discovery is already signigicantly high level
- by Kim, Jin-Gu Nov 18, 2019 04:47pm
- Global pharmaceutical companies are showing great interest in the development of new drugs using artificial intelligence (AI). It is expected that AI will drastically reduce the time and costs associated with finding a candidate substance through clinical trials and approvals before entering the market. What about the perspective of the
- Company
- Pfizer’s Upjohn changed in business name to Viatris
- by Eo, Yun-Ho Nov 18, 2019 06:23am
- Pfizer's Upjohn is expected to be reborn as a complete independent corporation, or one pharmaceutical company, next year. According to the relevant industry, Pfizer and Mylan decided to change the name of the company to Viatris in 2020 after the merger of the patent expiry division. This means complete company separation. Currently,
